NCT06130449View on ClinicalTrials.gov

Testosterone and Neural Function

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Spinal Cord Injury
Interventions
DRUG

Natesto testosterone intranasal gel

A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.

DRUG

Ayr Saline Nasal Gel

A single dose of Ayr (one spray per nostril) will be administered to each participant.

Trial Locations (1)

10468-3904

RECRUITING

James J. Peters VA Medical Center, Bronx, NY, The Bronx

All Listed Sponsors
lead

VA Office of Research and Development

FED